Codex DNA

Avitide discovers, develops, manufactures and supplies custom and catalog biopharmaceutical affinity purification solutions to the biopharmaceutical industry. Avitide’s proprietary AVIPure™ affinity ligand portfolio sets the standard for precise affinity separations and consistent robust performance for its high-valued chromatographic products. Avitide develops these technologies with an industry-leading 3-month, concept to resin delivery service timeline that enables industry biopharmaceutical manufacturers and contract developers to achieve faster bioprocess development timelines, improved process economics, predictable scalability, and enable next-generation integrated continuous downstream processing. Avitide’s commercial resin manufacturing and supply operates under an ISO 9001:2015 quality management system and has been successfully audited for its quality systems and continuity of supply plan for its affinity chromatography products. Avitide has successfully deployed affinity purification technologies towards an array of biological molecules including enzymes, bispecific antibodies, therapeutic scaffolds, growth factors, hormones, insulins, blood factors, Fcfusions, cell-based therapies, vaccines, and gene therapy viral vectors. Avitide's management team brings substantial industry expertise and a successful track record in commercializing innovative biopharmaceutical manufacturing platforms. Avitide is financed by premier venture capital and private equity firms, including Polaris Venture Partners, OrbiMed Advisors, Mithril Capital Management, Sands
Capital Ventures, Section 32, SV Health Investors, Borealis Ventures, and NeoMed Management. For more information, visit www.avitide.com.

Fina Biosolutions LLC is a privately held research and development stage biotechnology company that discovers, develops, and collaborates to commercialize novel vaccine conjugates for prevention of life-threatening diseases. Fina has patented novel techniques to conjugate, purify, and manufacture conjugates using its proprietary chemistry to create complex conjugate vaccines. The technology is currently licensed by leading vaccine manufacturers in both Europe and Asia, including GlaxoSmithKline for marketed vaccines Synflorix™ Menitorix™, Nimenrix™, The Serum Institute of India Ltd., The Chengdu Institute of Biological Products and others. Fina Bosolutions also manufactures E. coli expressed
CRM197 conjugate vaccine carrier portein.

Fina BioSolutions also develops polymer based diagnostic reagents, amino dextran, and antibody dextran conjugates.

ImQuest BioSciences is a preclinical contract research and development organization (CRO) that provides services to evaluate the potential of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory diseases.

As part of our ImQuest SUCCESS platform, we provide expert preclinical research services, including compound screening to define compound efficacy and drug target validation analysis to define the mechanism of action and toxicity of pharmaceutical products. We specialize in the development of small molecules, natural products, biologics, antimicrobial peptides, therapeutic antibodies and vaccines for infectious disease and cancer drug development programs.

Our preclinical contract research services are comprised of interrelated efficacy-defining components for infectious disease (including microbiology and virology), cancer and women's health with parallel evaluations of in vitro and ex vivo toxicity and the pharmaceutical properties and chemical structure of preclinical candidates to efficiently validate you drug target.

We are committed to earning our client's trust and building long term relationships through collaboration, unwavering commitment to quality science and consistent and effective communication. Our team has decades of experience in the field of virology, microbiology and oncology. As such, we understand that each product and each client is unique and we strive to provide effective solutions.

Integrity Bio is a leader in protein formulation development. We help companies turn molecules into medicines by creating great formulations.

Our contract development organization is focused on the formulation and GMP filling of biologics. We have formulated over 200 biologics including vaccines, antibodies, proteins, and peptides for more than 100 firms. Integrity specializes in hard-to-formulate products in liquid and lyophilized forms.

In addition, Integrity Bio has developed proprietary products to solve development challenges or extend the product lifecycle. For lyophilized products, Integrity offers LyoTip, a simple to use reconstitution system that allows one step reconstitution and injection without complex mixing and set up procedures. www.lyotip.com

For IV products, Integrity has patented EXCELSE formulation technology that can lower viscosity, and convert lyophilized and liquid IV drugs into ready to use liquid subcutaneous concentrations.

RiboWiz Scientific is a digital biotechnology company integrating both A.I. software and life science. RiboWiz offers customized service and cloud-based subscription licensing to accurately predict and maximize recombinant protein production for life science companies using proprietary RiboScan™ software platform.

Creating high-value recombinant proteins, e.g. biologics, enzymes, vaccines, antibodies, and pesticides, is important to life science companies across a broad range of industrial applications. For example, proteins can be over-expressed for use in basic research, used as insecticides, or used as targets for small molecule drugs or antibodies for the treatments of AIDS, diabetes, cancer and other diseases.

Many R&D projects are stymied by conventional protein expression methods that require multiple trial-and-error laboratory testing to produce proteins at the desired level. RiboScan™ provides more of the desired protein candidates with fewer folding errors and protein aggregations by simulating and modulating ribosomal speed and accuracy during protein synthesis.

Unlike current alternatives that require synthesis and laboratory testing of hundreds of genes construct, RiboScan™ accurately predicts protein expression levels and designs an optimized gene construct with minimal subsequent laboratory testing. This significantly accelerates clients’ R&D projects, reduces costs, expedites innovations, and enhances protein quality to make clients more competitive in bringing multiple novel compounds to market faster.

RiboWiz’s mission is to help clients successfully produce high-value, difficult-to-make recombinant proteins faster for new treatments of diseases and also for the advancement of medicine and biotechnology.